Dr. Jennifer Lea Dearborn-Tomazos, MD

Dr. Dearborn-Tomazos practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Dearborn-Tomazos' NPI, 1144457755, was assigned on June 22, 2009. Dr. Dearborn-Tomazos graduated from University of Connecticut School of Medicine in 2009. Dr. Dearborn-Tomazos holds Connecticut license 53070.

Dr. Dearborn-Tomazos' primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Dearborn-Tomazos' primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Dearborn-Tomazos is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Dearborn-Tomazos to 4 more hospitals and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dearborn-Tomazos practices, 6 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Dearborn-Tomazos' primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Dearborn-Tomazos is licensed in Connecticut.

CMS data shows 819 Medicare services from Dr. Dearborn-Tomazos across 10 procedure codes in 2024, for 287 Medicare patients. Medicare paid $74,315 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 287 Medicare patients who saw Dr. Dearborn-Tomazos in 2024. The largest group is 75 to 84, with 113 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dearborn-Tomazos' median patient age at 72, with 52% women.

In 2024, Dr. Dearborn-Tomazos wrote 346 Medicare Part D claims for 64 patients. 88% of them were for generic drugs. CMS names the drug for 238 of them, across 11 drugs with 11 or more claims each, at $31,029 in total drug cost. In 2023, CMS named 226 claims across 9 drugs.

Dr. Dearborn-Tomazos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dearborn-Tomazos as offering telehealth.

Dmand AI links 7 papers to Dr. Dearborn-Tomazos, published from 2019 to 2025. 2021 was the busiest year, with 2. The most frequent topics are Stroke, Embolic Stroke and Hydroxymethylglutaryl-CoA Reductase Inhibitors. Dr. Dearborn-Tomazos' most frequent co-authors are Magdy H. Selim, MD, Ryan Davidson Barrette, MD and John Concato, MD.

CMS Open Payments shows 26 general payments to Dr. Dearborn-Tomazos from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 90% of the total. Pfizer Inc. paid the most, $19,150. It also lists 5 research payments totaling $4,725 from 2021 to 2025, naming 1 clinical trial.

Dr. Dearborn-Tomazos graduated from University of Connecticut School of Medicine in 2009.